Alternative splicing is a process that lets a single gene produce multiple different proteins. It works by rearranging which segments of a gene’s instructions get included in the final message that cells use to build proteins. This is one of the main reasons humans can function with only about 20,000 protein-coding genes yet produce a far larger variety of proteins. Up to 95% of human multi-exon genes undergo alternative splicing, making it one of the most widespread mechanisms for generating biological complexity.
From Gene to Protein: The Basics
To understand alternative splicing, you need a quick picture of how genes work. A gene’s DNA is first copied into a preliminary RNA message called pre-mRNA. This raw message contains two types of segments: exons, which carry the actual protein-building instructions, and introns, which are spacer regions that need to be removed. In standard splicing, a cell’s machinery clips out all the introns and stitches the exons together in order, creating a clean mRNA message that ribosomes can read to assemble a protein.
Alternative splicing is what happens when the cell doesn’t always stitch the exons together in the same way. Some exons can be skipped entirely. Others can be swapped for a different version. Introns that are normally removed can occasionally be kept in. Each combination produces a slightly different mRNA, which in turn produces a different version of the protein, called an isoform. One gene can generate dozens of isoforms this way.
How the Spliceosome Works
The molecular machine responsible for splicing is the spliceosome, a large complex built from small nuclear proteins. Its core components recognize three key signals embedded in the pre-mRNA: the start of an intron (the 5′ splice site), a branch point sequence inside the intron, and the end of the intron (the 3′ splice site). The spliceosome assembles in stages, progressing through a series of intermediate complexes. At each stage, energy-consuming enzymes reshape the RNA, ultimately cutting out the intron and joining the flanking exons together.
The spliceosome doesn’t always lock onto the same signals with equal strength, and that flexibility is exactly what makes alternative splicing possible. Depending on which splice sites are recognized or ignored in a given cell, the final mRNA can look very different from one tissue or developmental stage to another.
Main Patterns of Alternative Splicing
Alternative splicing takes several forms, each producing a different kind of change in the final protein:
- Exon skipping: An exon that is normally included gets left out entirely. This is the most common pattern in mammals.
- Intron retention: An intron that is normally removed stays in the final mRNA, adding extra sequence to the protein or sometimes preventing the protein from being made at all.
- Alternative 5′ or 3′ splice sites: The spliceosome cuts at a different position within the same exon, making that exon slightly longer or shorter than usual.
- Mutually exclusive exons: Two or more exons are never included in the same mRNA. The cell always picks one or the other, producing distinct protein versions.
These patterns can also be combined. A single gene might use exon skipping in one tissue and an alternative splice site in another, multiplying the number of possible protein products.
What Controls Which Version Gets Made
Cells don’t splice randomly. Two families of regulatory proteins act as the main decision-makers. SR proteins function as splicing activators: when they bind to regions called splicing enhancers on the pre-mRNA, they increase the chance that a nearby splice site will be used, encouraging the inclusion of a particular exon. Working in the opposite direction, hnRNP proteins act as splicing repressors. They bind to silencer elements on the RNA and reduce the likelihood that a nearby site will be recognized as a splice junction, leading to exon skipping.
The balance between these activators and repressors varies from tissue to tissue and even changes over time within the same cell. A muscle cell and a brain cell reading the same gene can produce entirely different proteins simply because they have different concentrations of SR proteins and hnRNPs. Signals from outside the cell, such as hormones or stress responses, can also shift this balance, making alternative splicing a dynamic, responsive process rather than a fixed one.
Why It Matters for Protein Diversity
The human genome contains roughly 20,000 protein-coding genes, yet the actual number of distinct proteins the body produces is vastly larger. Alternative splicing is one of the primary explanations for this gap. RNA sequencing of human organs has shown that transcripts from more than 95% of multi-exon genes undergo alternative splicing, meaning nearly every gene with more than one exon is producing multiple protein variants.
These isoforms aren’t just minor variations. Different versions of the same protein can have entirely different functions, different lifespans inside the cell, or different abilities to interact with other molecules. This is how a relatively compact genome generates the complexity needed to build and maintain hundreds of specialized cell types across the human body.
Alternative Splicing and Disease
When splicing goes wrong, the consequences can be severe. Mutations that disrupt splice sites, or that alter the binding of regulatory proteins, can cause the wrong protein isoform to be produced, or prevent a functional protein from being made at all.
Spinal muscular atrophy (SMA) is one of the clearest examples. More than 90% of SMA cases result from the loss of a gene called SMN1. Humans carry a nearly identical backup gene, SMN2, but it doesn’t compensate because the spliceosome predominantly skips one critical exon during SMN2 processing. Without that exon, the resulting protein is unstable and quickly broken down. The disease causes progressive muscle weakness and, in its most severe forms, can be fatal in early childhood.
In cancer, altered splicing patterns are increasingly recognized as contributors to tumor growth. The gene for vascular endothelial growth factor (VEGF), a protein involved in building new blood vessels, produces different isoforms depending on which splice sites are used. Some of those isoforms promote the blood vessel growth that tumors need to sustain themselves, while others have the opposite effect. Shifts in the balance between these isoforms are observed across multiple cancer types.
Medicines That Fix Splicing Errors
The understanding of alternative splicing has opened a new category of therapy: drugs designed not to replace a missing protein, but to correct the splicing process itself. These drugs, called splice-switching antisense oligonucleotides, are short synthetic strands of modified RNA that bind to specific spots on pre-mRNA and change how the spliceosome reads it.
The first major success was nusinersen (sold as Spinraza), approved for spinal muscular atrophy. It works by binding to a silencer element in the SMN2 gene’s pre-mRNA, blocking the signal that normally causes the spliceosome to skip the critical exon. With that silencer masked, the exon gets included, and cells produce a functional protein. The results in patients have been significant enough to transform SMA from a condition with very limited treatment options into one with an approved, effective therapy.
The FDA has now approved five splice-modulating drugs in total, including several for Duchenne muscular dystrophy. In 2018, the agency also permitted the first “N-of-1” study of a custom-designed splicing drug, milasen, built for a single patient with Batten disease. That case demonstrated the potential for personalized medicines targeting an individual’s specific splicing defect.
A Brief Note on Discovery
The existence of introns, and the realization that genes are “split” into coding and non-coding segments, was itself a surprise. Richard J. Roberts and Phillip A. Sharp received the 1993 Nobel Prize in Physiology or Medicine for discovering split genes, a finding that upended the assumption that genes were continuous stretches of DNA copied straight into protein instructions. That discovery laid the groundwork for everything scientists now understand about how alternative splicing generates protein diversity from a finite genome.